+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neuromyelitis Optica Spectrum Disorder Market 2023-2027

  • PDF Icon

    Report

  • 138 Pages
  • June 2023
  • Region: Global
  • TechNavio
  • ID: 5868361
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neuromyelitis optica spectrum disorder market is forecasted to grow by USD 173.48 mn during 2022-2027, accelerating at a CAGR of 6.16% during the forecast period. The report on the neuromyelitis optica spectrum disorder market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, approval of novel therapeutics and strong drug pipeline, and increasing incidence of neuromyelitis optica spectrum disorder.

The neuromyelitis optica spectrum disorder market is segmented as below:

By Application

  • Hospitals
  • Specialty clinics
  • Homecare

By Type

  • With aquaporin-4 antibodies
  • Without aquaporin-4 antibodies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the advances in treatment of NMOSD as one of the prime reasons driving the neuromyelitis optica spectrum disorder market growth during the next few years. Also, growing healthcare expenditure and increase in strategic alliances will lead to sizable demand in the market.

The report on the neuromyelitis optica spectrum disorder market covers the following areas:

  • Neuromyelitis optica spectrum disorder market sizing
  • Neuromyelitis optica spectrum disorder market forecast
  • Neuromyelitis optica spectrum disorder market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neuromyelitis optica spectrum disorder market vendors that include AstraZeneca, Biogen Inc., Chugai Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., HBM Holdings Ltd., Horizon Therapeutics Plc, TG Therapeutics Inc., Mitsubishi Chemical Group Corp., and Opexa Therapeutics Inc.. Also, the neuromyelitis optica spectrum disorder market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global neuromyelitis optica spectrum disorder market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global neuromyelitis optica spectrum disorder market 2017 - 2021 ($ million)
4.2 Application Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Application Segment 2017 - 2021 ($ million)
4.3 Type Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Application
6.1 Market segments
Exhibit 30: Chart on Application - Market share 2022-2027 (%)
Exhibit 31: Data Table on Application - Market share 2022-2027 (%)
6.2 Comparison by Application
Exhibit 32: Chart on Comparison by Application
Exhibit 33: Data Table on Comparison by Application
6.3 Hospitals - Market size and forecast 2022-2027
Exhibit 34: Chart on Hospitals - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)
6.4 Speciality clinics - Market size and forecast 2022-2027
Exhibit 38: Chart on Speciality clinics - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Speciality clinics - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Speciality clinics - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Speciality clinics - Year-over-year growth 2022-2027 (%)
6.5 Homecare - Market size and forecast 2022-2027
Exhibit 42: Chart on Homecare - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Data Table on Homecare - Market size and forecast 2022-2027 ($ million)
Exhibit 44: Chart on Homecare - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on Homecare - Year-over-year growth 2022-2027 (%)
6.6 Market opportunity by Application
Exhibit 46: Market opportunity by Application ($ million)
Exhibit 47: Data Table on Market opportunity by Application ($ million)
7 Market Segmentation by Type
7.1 Market segments
Exhibit 48: Chart on Type - Market share 2022-2027 (%)
Exhibit 49: Data Table on Type - Market share 2022-2027 (%)
7.2 Comparison by Type
Exhibit 50: Chart on Comparison by Type
Exhibit 51: Data Table on Comparison by Type
7.3 With aquaporin-4 antibodies - Market size and forecast 2022-2027
Exhibit 52: Chart on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Data Table on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
Exhibit 54: Chart on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
Exhibit 55: Data Table on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
7.4 Without aquaporin-4 antibodies - Market size and forecast 2022-2027
Exhibit 56: Chart on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Data Table on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
Exhibit 58: Chart on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
7.5 Market opportunity by Type
Exhibit 60: Market opportunity by Type ($ million)
Exhibit 61: Data Table on Market opportunity by Type ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 UK - Market size and forecast 2022-2027
Exhibit 87: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.9 China - Market size and forecast 2022-2027
Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)
9.10 Canada - Market size and forecast 2022-2027
Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.11 India - Market size and forecast 2022-2027
Exhibit 99: Chart on India - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on India - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on India - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on India - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ million)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 AstraZeneca
Exhibit 111: AstraZeneca - Overview
Exhibit 112: AstraZeneca - Product/Service
Exhibit 113: AstraZeneca - Key news
Exhibit 114: AstraZeneca - Key offerings
12.4 Biogen Inc.
Exhibit 115: Biogen Inc. - Overview
Exhibit 116: Biogen Inc. - Product/Service
Exhibit 117: Biogen Inc. - Key offerings
12.5 Chugai Pharmaceutical Co. Ltd.
Exhibit 118: Chugai Pharmaceutical Co. Ltd. - Overview
Exhibit 119: Chugai Pharmaceutical Co. Ltd. - Product/Service
Exhibit 120: Chugai Pharmaceutical Co. Ltd. - Key offerings
12.6 F. Hoffmann La Roche Ltd.
Exhibit 121: F. Hoffmann La Roche Ltd. - Overview
Exhibit 122: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 123: F. Hoffmann La Roche Ltd. - Key news
Exhibit 124: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 125: F. Hoffmann La Roche Ltd. - Segment focus
12.7 HBM Holdings Ltd.
Exhibit 126: HBM Holdings Ltd. - Overview
Exhibit 127: HBM Holdings Ltd. - Product/Service
Exhibit 128: HBM Holdings Ltd. - Key offerings
12.8 Horizon Therapeutics Plc
Exhibit 129: Horizon Therapeutics Plc - Overview
Exhibit 130: Horizon Therapeutics Plc - Business segments
Exhibit 131: Horizon Therapeutics Plc - Key news
Exhibit 132: Horizon Therapeutics Plc - Key offerings
Exhibit 133: Horizon Therapeutics Plc - Segment focus
12.9 Mitsubishi Chemical Group Corp.
Exhibit 134: Mitsubishi Chemical Group Corp. - Overview
Exhibit 135: Mitsubishi Chemical Group Corp. - Business segments
Exhibit 136: Mitsubishi Chemical Group Corp. - Key offerings
Exhibit 137: Mitsubishi Chemical Group Corp. - Segment focus
12.10 Opexa Therapeutics Inc.
Exhibit 138: Opexa Therapeutics Inc. - Overview
Exhibit 139: Opexa Therapeutics Inc. - Product/Service
Exhibit 140: Opexa Therapeutics Inc. - Key offerings
12.11 TG Therapeutics Inc.
Exhibit 141: TG Therapeutics Inc. - Overview
Exhibit 142: TG Therapeutics Inc. - Product/Service
Exhibit 143: TG Therapeutics Inc. - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 144: Inclusions checklist
Exhibit 145: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 146: Currency conversion rates for US$
13.4 Research methodology
Exhibit 147: Research methodology
Exhibit 148: Validation techniques employed for market sizing
Exhibit 149: Information sources
13.5 List of abbreviations
Exhibit 150: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Application
Exhibits 6: Executive Summary - Chart on Market Segmentation by Type
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 18: Historic Market Size - Data Table on global neuromyelitis optica spectrum disorder market 2017 - 2021 ($ million)
Exhibits 19: Historic Market Size - Application Segment 2017 - 2021 ($ million)
Exhibits 20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2022 and 2027
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits 26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits 27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits 28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits 29: Chart on Market condition - Five forces 2022 and 2027
Exhibits 30: Chart on Application - Market share 2022-2027 (%)
Exhibits 31: Data Table on Application - Market share 2022-2027 (%)
Exhibits 32: Chart on Comparison by Application
Exhibits 33: Data Table on Comparison by Application
Exhibits 34: Chart on Hospitals - Market size and forecast 2022-2027 ($ million)
Exhibits 35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million)
Exhibits 36: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
Exhibits 37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)
Exhibits 38: Chart on Speciality clinics - Market size and forecast 2022-2027 ($ million)
Exhibits 39: Data Table on Speciality clinics - Market size and forecast 2022-2027 ($ million)
Exhibits 40: Chart on Speciality clinics - Year-over-year growth 2022-2027 (%)
Exhibits 41: Data Table on Speciality clinics - Year-over-year growth 2022-2027 (%)
Exhibits 42: Chart on Homecare - Market size and forecast 2022-2027 ($ million)
Exhibits 43: Data Table on Homecare - Market size and forecast 2022-2027 ($ million)
Exhibits 44: Chart on Homecare - Year-over-year growth 2022-2027 (%)
Exhibits 45: Data Table on Homecare - Year-over-year growth 2022-2027 (%)
Exhibits 46: Market opportunity by Application ($ million)
Exhibits 47: Data Table on Market opportunity by Application ($ million)
Exhibits 48: Chart on Type - Market share 2022-2027 (%)
Exhibits 49: Data Table on Type - Market share 2022-2027 (%)
Exhibits 50: Chart on Comparison by Type
Exhibits 51: Data Table on Comparison by Type
Exhibits 52: Chart on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
Exhibits 53: Data Table on With aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
Exhibits 54: Chart on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
Exhibits 55: Data Table on With aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
Exhibits 56: Chart on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
Exhibits 57: Data Table on Without aquaporin-4 antibodies - Market size and forecast 2022-2027 ($ million)
Exhibits 58: Chart on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
Exhibits 59: Data Table on Without aquaporin-4 antibodies - Year-over-year growth 2022-2027 (%)
Exhibits 60: Market opportunity by Type ($ million)
Exhibits 61: Data Table on Market opportunity by Type ($ million)
Exhibits 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 63: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 64: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 65: Chart on Geographic comparison
Exhibits 66: Data Table on Geographic comparison
Exhibits 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibits 69: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits 70: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibits 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibits 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibits 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 83: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibits 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibits 85: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits 86: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits 87: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 88: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibits 89: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibits 90: Data Table on UK - Year-over-year growth 2022-2027 (%)
Exhibits 91: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibits 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibits 93: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibits 94: Data Table on China - Year-over-year growth 2022-2027 (%)
Exhibits 95: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits 96: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibits 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 99: Chart on India - Market size and forecast 2022-2027 ($ million)
Exhibits 100: Data Table on India - Market size and forecast 2022-2027 ($ million)
Exhibits 101: Chart on India - Year-over-year growth 2022-2027 (%)
Exhibits 102: Data Table on India - Year-over-year growth 2022-2027 (%)
Exhibits 103: Market opportunity By Geographical Landscape ($ million)
Exhibits 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 105: Impact of drivers and challenges in 2022 and 2027
Exhibits 106: Overview on Criticality of inputs and Factors of differentiation
Exhibits 107: Overview on factors of disruption
Exhibits 108: Impact of key risks on business
Exhibits 109: Vendors covered
Exhibits 110: Matrix on vendor position and classification
Exhibits 111: AstraZeneca - Overview
Exhibits 112: AstraZeneca - Product/Service
Exhibits 113: AstraZeneca - Key news
Exhibits 114: AstraZeneca - Key offerings
Exhibits 115: Biogen Inc. - Overview
Exhibits 116: Biogen Inc. - Product/Service
Exhibits 117: Biogen Inc. - Key offerings
Exhibits 118: Chugai Pharmaceutical Co. Ltd. - Overview
Exhibits 119: Chugai Pharmaceutical Co. Ltd. - Product/Service
Exhibits 120: Chugai Pharmaceutical Co. Ltd. - Key offerings
Exhibits 121: F. Hoffmann La Roche Ltd. - Overview
Exhibits 122: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 123: F. Hoffmann La Roche Ltd. - Key news
Exhibits 124: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 125: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 126: HBM Holdings Ltd. - Overview
Exhibits 127: HBM Holdings Ltd. - Product/Service
Exhibits 128: HBM Holdings Ltd. - Key offerings
Exhibits 129: Horizon Therapeutics Plc - Overview
Exhibits 130: Horizon Therapeutics Plc - Business segments
Exhibits 131: Horizon Therapeutics Plc - Key news
Exhibits 132: Horizon Therapeutics Plc - Key offerings
Exhibits 133: Horizon Therapeutics Plc - Segment focus
Exhibits 134: Mitsubishi Chemical Group Corp. - Overview
Exhibits 135: Mitsubishi Chemical Group Corp. - Business segments
Exhibits 136: Mitsubishi Chemical Group Corp. - Key offerings
Exhibits 137: Mitsubishi Chemical Group Corp. - Segment focus
Exhibits 138: Opexa Therapeutics Inc. - Overview
Exhibits 139: Opexa Therapeutics Inc. - Product/Service
Exhibits 140: Opexa Therapeutics Inc. - Key offerings
Exhibits 141: TG Therapeutics Inc. - Overview
Exhibits 142: TG Therapeutics Inc. - Product/Service
Exhibits 143: TG Therapeutics Inc. - Key offerings
Exhibits 144: Inclusions checklist
Exhibits 145: Exclusions checklist
Exhibits 146: Currency conversion rates for US$
Exhibits 147: Research methodology
Exhibits 148: Validation techniques employed for market sizing
Exhibits 149: Information sources
Exhibits 150: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global neuromyelitis optica spectrum disorder market: AstraZeneca, Biogen Inc., Chugai Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., HBM Holdings Ltd., Horizon Therapeutics Plc, TG Therapeutics Inc., Mitsubishi Chemical Group Corp., and Opexa Therapeutics Inc..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is advances in treatment of NMOSD.'

According to the report, one of the major drivers for this market is the growing geriatric population.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca
  • Biogen Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • HBM Holdings Ltd.
  • Horizon Therapeutics Plc
  • TG Therapeutics Inc.
  • Mitsubishi Chemical Group Corp.
  • Opexa Therapeutics Inc.